These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 34745006)

  • 21. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
    Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
    Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes.
    Ciardullo S; Savaré L; Rea F; Perseghin G; Corrao G
    Diabetes Metab Res Rev; 2024 May; 40(4):e3791. PubMed ID: 38549238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
    Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV
    Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anti-Proteinuric Effect of GLP1-RA as Add-On to SGLT2-i and ACE-i in a Diabetic Patient with IgA Nephropathy].
    Malighetti ME; Faletto M
    G Ital Nefrol; 2024 Apr; 41(2):. PubMed ID: 38695228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration.
    Isshiki M; Sakuma I; Hayashino Y; Sumita T; Hara K; Takahashi K; Shiojima I; Satoh-Asahara N; Kitazato H; Ito D; Saito D; Hatano M; Ikegami Y; Iida S; Shimada A; Noda M
    Endocr J; 2020 Nov; 67(11):1127-1138. PubMed ID: 32612066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.
    Mentz RJ; Stevens SR; DeVore AD; Lala A; Vader JM; AbouEzzeddine OF; Khazanie P; Redfield MM; Stevenson LW; O'Connor CM; Goldsmith SR; Bart BA; Anstrom KJ; Hernandez AF; Braunwald E; Felker GM
    JACC Heart Fail; 2015 Feb; 3(2):97-107. PubMed ID: 25543972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.
    Berra C; Manfrini R; Regazzoli D; Radaelli MG; Disoteo O; Sommese C; Fiorina P; Ambrosio G; Folli F
    Pharmacol Res; 2020 Oct; 160():105052. PubMed ID: 32650058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
    Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
    Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there a role for renin profiling in selecting chronic heart failure patients for ACE inhibitor treatment?
    Lim PO; MacFadyen RJ; Struthers AD
    Heart; 2000 Mar; 83(3):257-61. PubMed ID: 10677399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.
    Schork A; Saynisch J; Vosseler A; Jaghutriz BA; Heyne N; Peter A; Häring HU; Stefan N; Fritsche A; Artunc F
    Cardiovasc Diabetol; 2019 Apr; 18(1):46. PubMed ID: 30953516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists.
    Myasoedova VA; Bozzi M; Valerio V; Moschetta D; Massaiu I; Rusconi V; Di Napoli D; Ciccarelli M; Parisi V; Agostoni P; Genovese S; Poggio P
    Antioxidants (Basel); 2023 Dec; 13(1):. PubMed ID: 38275636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus.
    Price DA; De'Oliveira JM; Fisher ND; Williams GH; Hollenberg NK
    Am J Hypertens; 1999 Apr; 12(4 Pt 1):348-55. PubMed ID: 10232494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low plasma aldosterone despite normal plasma renin activity in uncomplicated type 1 diabetes mellitus: effects of RAAS stimulation.
    Luik PT; Kerstens MN; Hoogenberg K; Navis GJ; Dullaart RP
    Eur J Clin Invest; 2003 Sep; 33(9):787-93. PubMed ID: 12925038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence.
    Muller DRP; Stenvers DJ; Malekzadeh A; Holleman F; Painter RC; Siegelaar SE
    Front Endocrinol (Lausanne); 2023; 14():1215356. PubMed ID: 37881498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Normotensive sodium loading in normal man: regulation of renin secretion during beta-receptor blockade.
    Mølstrøm S; Larsen NH; Simonsen JA; Washington R; Bie P
    Am J Physiol Regul Integr Comp Physiol; 2009 Feb; 296(2):R436-45. PubMed ID: 19073901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.
    Brown E; Heerspink HJL; Cuthbertson DJ; Wilding JPH
    Lancet; 2021 Jul; 398(10296):262-276. PubMed ID: 34216571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A role for tubular Na
    Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
    Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice.
    Miyata KN; Lo CS; Zhao S; Liao MC; Pang Y; Chang SY; Peng J; Kretzler M; Filep JG; Ingelfinger JR; Zhang SL; Chan JSD
    Clin Sci (Lond); 2021 Apr; 135(7):943-961. PubMed ID: 33822013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.